Category: Uncategorised

First UK Neuro Forum

UK Neuro Forum will focus on services and support for neuro conditions 28 November 2024: Andrew Gwynne MP, Parliamentary Under-Secretary of State at the Department of Health and Social Care, has announced today that a new UK Neuro Forum will be set up to find ways to improve care and support for people affected by…

Digital therapies for tic disorders 

NICE are performing a technology assessment to look at digital enabled therapy for tic disorders in children and young people NICE will assess digital therapies for tic disorders in children and young people to determine whether they can be recommended for use in the NHS, based on the available evidence and cost-saving potential. They are…

Could shared medical appointments increase patient engagement?

New research from ESMT Berlin finds that shared medical appointments increase engagement from patients as they ask more questions, make more comments, and exhibit higher levels of nonverbal engagement, providing greater value for other patients in the sessions. One-on-one service delivery is often considered ideal, with individualised attention assumed to improve client outcomes. In shared service delivery,…

Seer partners with NHS hospitals

Seer partners with NHS hospitals to deliver cloud-based video-EEG-ECG monitoring services that enhance the efficiency of neurology and neurophysiology teams. Seer supports the integration of home-based diagnostics into current clinical workflows through the Seer Home service, a range of home video telemetry offerings. Hospitals can access customised services — including patient set-up, home-based monitoring, data…

Ipsen at the World Congress for Neurorehabilitation

Ipsen had a robust presence at the 12th World Congress for Neurorehabilitation (WCNR) in Vienna, Austria and virtually, from 14-17 December 2022, further demonstrating the company’s long-standing partnership with the World Federation for Neurorehabilitation (WFNR) and ongoing commitment to neuroscience. In addition to showcasing the company’s latest neuroscience clinical data, Ipsen hosted a satellite symposium…

First autopsy-confirmed results for identifying Alzheimer’s in presence of other co-morbid pathologies using DISCERN test

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialisation of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients” in Scientific Reports. Up until now, there have been no autopsy-validated tests shown to accurately identify AD…

Laser Therapy for Epilepsy now available on the NHS

NHS England has accepted the recommendation of the Clinical Priorities Advisory Group to roll out LITT (laser interstitial thermal therapy) on the NHS. LITT is a laser treatment for epilepsy offering a less invasive alternative to conventional neurosurgery. It is a stereotactic procedure with the potential for seizure reduction results similar to those of open resection, with…

NICE publishes draft guidance on access to Duchenne treatment Translarna

NICE has published draft guidance stating that although Translarna (also known as ataluren) is clinically effective and an innovative treatment, there is doubt as to its cost effectiveness. NICE’s draft recommendation is that people currently receiving Translarna should continue to have access to it until they and their NHS clinician consider it appropriate to stop,…

Breakthrough in identifying common neural processes in Parkinson’s disease

New research could lead to treatments that halt the advance of Parkinson’s disease. Study from University of Haifa could have significant implications for how Parkinson’s disease is treated following a breakthrough in identifying common neural processes for the first time. A new study conducted by University of Haifa has identified processes that may help prevent…

AJOVY®▼ (fremanezumab) for treatment of migraine in patients with co-morbid depression

Teva Pharmaceutical  Industries Ltd. announced on 8th September 2022 the results of two studies1,2 presented at the Migraine Trust International Symposium (MTIS) in London, UK, which demonstrate the efficacy of AJOVY▼ (fremanezumab) in migraine patients who also experience depression or anxiety.  AJOVY▼ (fremanezumab) is indicated for the prevention of migraine in adults with at least…